CUREVO

curevo-logo

Curevo is a clinical-stage biotech firm focused on producing next-generation vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and the desired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market.

#SimilarOrganizations #People #Financial #Website #More

CUREVO

Social Links:

Industry:
Biopharma Biotechnology

Founded:
2018-01-01

Website Url:
http://www.curevovaccine.com

Total Employee:
1+

Status:
Active

Contact:
1(206)492-5722

Total Funding:
60 M USD

Technology used in webpage:
Domain Not Resolving Microsoft Exchange Online


Similar Organizations

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

eikonoklastes-therapeutics-logo

Eikonoklastes Therapeutics

Eikonoklastes Therapeutics is a preclinical-stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies.

Current Employees Featured

george-simeon_image

George Simeon
George Simeon CEO @ Curevo
CEO
2019-02-01

Investors List

janus-henderson-investors_image

Janus Henderson Investors

Janus Henderson Investors investment in Series A - Curevo

e-networks-venture-investment_image

E&Investment

E&Investment investment in Series A - Curevo

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series A - Curevo

green-cross-holdings-corp_image

Green Cross Holding Corp

Green Cross Holding Corp investment in Series A - Curevo

adjuvant-capital_image

Adjuvant Capital

Adjuvant Capital investment in Series A - Curevo

Official Site Inspections

http://www.curevovaccine.com

  • Host name: 192.0.78.148
  • IP address: 192.0.78.148
  • Location: San Francisco United States
  • Latitude: 37.7506
  • Longitude: -122.4121
  • Metro Code: 807
  • Timezone: America/Los_Angeles
  • Postal: 94110

Loading ...

More informations about "Curevo"

About Us - Curevo Vaccine

By curevovaccine. 12 Jan, 2025. Press Releases. Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine. by curevovaccine. 08 Jan, 2025. Press Releases. Curevo Vaccine to present at the 43rd Annual โ€ฆSee details»

Management Team - Curevo Vaccine

Executive Team Board of Directors Scientific Advisors Executive Team Linkedin George Simeon CEO & Board Director George Simeon is the CEO of Curevo Vaccine. He joined Curevo at the beginning of 2019 and has over 30 years of โ€ฆSee details»

Curevo - Crunchbase Company Profile & Funding

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as โ€ฆSee details»

Curevo Vaccine - LinkedIn

Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent โ€ฆSee details»

Curevo, Inc. - Drug pipelines, Patents, Clinical trials - Synapse

Curevovaccine.com. Startups | Holding Company | 2018 | Washington, United States | 10-50 | curevovaccine.com. Last update 07 Mar 2025. Overview. Pipeline. Deal. Translational โ€ฆSee details»

Curevo Vaccine 2025 Company Profile: Valuation, Funding

Curevo Vaccine General Information Description. Developer of a clinical-stage adjuvanted subunit vaccine intended to improve efficacy and broaden immune response. The company leverages โ€ฆSee details»

Curevo Vaccine - VentureRadar

Website: http://www.curevovaccine.com/ They combine excellence in protein structural biology and adjuvant / vaccine formulation to create the next generation of ...See details»

Curevo Vaccine Company Profile | Management and Employees โ€ฆ

[email protected]: Curevo Vaccine Top Competitors. Company Employees Revenue Top technologies; Regenerative Medicine Now. 6: $5.5 M: PAI Life Sciences Inc. 8: $1.5 M: โ€ฆSee details»

Curevo Vaccine Inc. - BIO Investor Forum | BIO

The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... www.curevovaccine.com. โ€ฆSee details»

Our History - Curevo Vaccine

Our Mission Safety. Supply. Efficacy. By combining excellence in protein and adjuvant biology, we are focused on creating a new generation of adjuvanted subunit vaccines of global importance โ€ฆSee details»

Curevo Raises $110 Million to Advance Amezosvatein Shingles

Mar 17, 2025 Curevo Vaccine closes a $110 million Series B round led by Medicxi, with new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures....See details»

Founder Lodge | Curevo Vaccine raises $110,000,000 at Series B on โ€ฆ

19/03/2025; Series B; $110,000,000 ; Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) โ€ฆSee details»

Curevo Vaccine to present at the 43rd Annual J.P. Morgan

SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease โ€ฆSee details»

Curevo Vaccine Announces $26 Million Series A1 Financing to โ€ฆ

Nov 16, 2022 -- Curevoโ€™s lead program is CRV-101, an adjuvanted subunit vaccine for shingles, which has completed enrollment in a 678-patient Phase 2b head-to-head trial of CRV-101 โ€ฆSee details»

Curevo Vaccine Announces Robust Antibody Response Results of โ€ฆ

Sep 15, 2020 SEATTLE--(BUSINESS WIRE)--Sep 15, 2020-- Curevo Vaccine, a clinical stage biopharmaceutical company developing next generation vaccines for patients with infectious โ€ฆSee details»

Partnerships - Curevo Vaccine

As a nonprofit global research organization, MIBR (Mogam Institute for Biomedical Research) is engaged in basic discovery research to combat infectious diseases, cancer, and rare โ€ฆSee details»

Fully-funded Gavi, the Vaccine Alliance, is a lifeline for child ...

2 days ago Safeguarding children and adolescents from deadly, yet preventable diseases, such as polio, measles, diphtheria, pertussis, human papillomavirus and tetanus, among others, is โ€ฆSee details»

5 years of COVID-19 underscore value of coordinated efforts to โ€ฆ

Five years ago, on March 11, 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The novel coronavirus, dubbed SARS-CoV-2, began as a โ€ฆSee details»

GC Pharma to Establish Curevo - Curevo Vaccine

May 18, 2018 August 15, 2022 curevovaccine News, Vaccines No Comments. GC Pharma to Establish Curevo โ€“ a Seattle-based New Company Dedicated to Development of New โ€ฆSee details»

Curevo Vaccine (USA) Funding: $196M - medicalstartups.org

Mar 11, 2025 Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious...See details»

linkstock.net © 2022. All rights reserved